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DuraSeal Exact Is a Safe Adjunctive Treatment
for Durotomy in Spine: Postapproval Study
Kee D. Kim, MD1, Dinesh Ramanathan, MD, MPH1, Jason Highsmith, MD2,
William Lavelle, MD3, Peter Gerszten, MD,MPH4, Fernando Vale, MD5,
and Neill Wright MD6
Abstract
Study Design: A nonrandomized, two-armed prospective study.
Objective: Water-tight dural closure is paramount to the prevention of cerebrospinal fluid (CSF) leakage and associated
complications. Synthetic polyethylene glycol (PEG) hydrogel has been used as an adjunct to sutured dural repair; however, its
expansion postoperatively is a concern for neurological complications. A low-swell formulation of PEG sealant was introduced as
DuraSeal Exact Spine Sealant System (DESS). A Post-Approval Study was performed primarily to evaluate the safety and efficacy of
DESS for spinal dural repair compared to current alternatives, in a large patient population, reflecting a real-world practice.
Methods: A total of 36 sites in the United States enrolled 429 patients treated with DESS as an adjunct to dural repair in the
spinal sealant group and 406 patients treated with all other modalities in the control arm, from October 2011 to June 2016. The
primary endpoint was the incidence of CSF leak within 90 days of operation. The secondary endpoints evaluated were deep
surgical site infection and neurological serious adverse events.
Results: The CSF leakage in the DESS group (6.6%) was not significantly different from the control group (6.5%) (p ¼ .83), and
there was no significant difference in the time to first leak. The two groups had no significant differences in deep surgical site
infection (1.6% versus control 2.1%, p ¼ .61) or proportion of subjects with neurological serious adverse events (2.9% versus
control 1.6%, p ¼ .516).
Conclusions: DuraSeal Exact Spinal Sealant is safe when compared to current alternatives for spinal dural repair.
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Introduction
Dural opening in spinal operations, either intentional or inciden-
tal, is associated with a risk of cerebrospinal fluid (CSF) leak
postoperatively.1,2 Clinically, CSF leak manifests as postural
headache, often associated with nausea, vomiting, dizziness,
and photophobia. Persistent CSF leak often leads to collection
of a fluid pocket outside the confines of the dura mater, creating
a pseudomeningocele or a dural cutaneous fistula. This predis-
poses to infectious sequelae such as meningitis, or abscesses.3
Less common but more serious complications associated with
persistent CSF drainage include cerebellar hemorrhage and
intracranial subdural hematoma.4 Progressive pseudomeningo-
cele formation can lead to nerve root compression or even
herniation of neural elements causing neurological deficits.3
A watertight closure after dural openings can be an elusive
target, though critical in the prevention of complications. Primary
closure of spinal dural layer is usually achieved by suture,
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sometimes with the concomitant use of fat graft, muscle and/or
fascia.1,2,5Commonlyusedadjuncts to sutured repairmay include
the use of a collagen-based dural implant and/or a sealant.
DuraSeal (IntegraLife Sciences, Plainsboro,NJ) is a synthetic,
absorbable polyethylene glycol (PEG) hydrogel, developed for
use as a sealant in cranial and spinal dural repair.6-8 DuraSeal,
being hydrophilic in nature, has an intrinsic property to swell after
application. Reports of neurological complications due to mass
effect have been reported with use of DuraSeal in the spine.9-14
The original PEG hydrogel of DuraSeal was therefore modified
to a low-swell formulation, known as DuraSeal Exact Spine
Sealant (DESS).DESS is a synthetic, bioabsorbable hydrogel and
has desirable characteristics such as the ease of application, rapid
in situ polymerization, greater mechanical strength and elasticity.
A pivotal multicenter randomized trial evaluated the safety and
efficacy of DESS, leading to Food and Drug Administration
(FDA) approval for dural closure in the spine.15
Study Objective
Theobjective of this postapproval studywas to evaluate the safety
and efficacy of DESS as dural closure adjunct compared with the
available alternatives, in a real-world practice model. This study
was designed to evaluate incidence of postoperativeCSF leak and
adverse events in patients receiving DESS for treatment of inten-
tional or incidental durotomies, and to compare that to the corre-
sponding rates of alternative dural repair adjuncts.
Material and Methods
Study Design
This was a multicenter, nonrandomized, 2-arm postapproval
study designed to evaluate and compare postoperative CSF
leakage rates in subjects who received DESS and control sub-
jects who received other products and/or treatments to close
durotomies (both incidental and intentional). The DESS arm
consisted of subjects who underwent a spinal procedure where
DESS was administered, in addition to any other methods of
dural closure. Eligible subjects were enrolled prospectively
within 24 hours after completion of the spine surgery. The
control arm consisted of subjects who underwent a spinal pro-
cedure where the standard of care other than DESS was admi-
nistered. The subjects meeting study criteria were enrolled
either prospectively or retrospectively in this arm. Sites were
not required to enroll in both study arms.
The study consisted of 2 study visits: a screening visit/baseline
data collection and a 90-day postoperative follow-up visit
(+30 days). The follow-up included a physical examination,
complete neurologic examination, andwound healing evaluation.
Any reported adverse events were documented. All data was
collected on study-specific case report forms (CRFs) and housed
in the study-specific, 21 CFR Part 11 compliant, database.
The protocol was approved by the institutional review board
of all participating sites. Thirty-six centers participated in this
clinical investigation. All subjects provided written informed
consent prior to participation. The study has been registered on
http://clinicaltrials.gov (NCT01410864).
Participants
Patients were adults at least 18 years of age who had any spinal
operation where a dural opening (either intentional or inciden-
tal) occurred that needed repair. Pregnant and breastfeeding
females were excluded from the study as well as those subjects
who the investigator determined were not able to comply with
the required follow-up visits.
Treatment Response Assessments and Outcomes
Measures
The primary endpoint of the study was the occurrence of post-
operative CSF leak within 90 days after spine surgical procedure.
A CSF leak was defined as a CSF fistula or a pseudomeningocele
confirmed by clinical examination or diagnostic testing (ie, mag-
netic resonance imaging [MRI] or computed tomography [CT]),
whether or not treatment such as surgical repair or drainage was
required. The secondary endpoints of the study were the occur-
rence of deep surgical site infection (DSSI) and neurological
serious adverse event (SAE) within 90 days after the surgical
procedure. Serious adverse events included, but were not limited
to, those leading to a life-threatening illness or injury or those that
required inpatient hospitalization.
Statistical Analysis
The statistical analyses were produced using Statistical Anal-
ysis System version 9.3 (SAS Inc, Cary, NC). Unless otherwise
specified, the statistical comparisons were carried out using 2-
tailed tests, with type 1 error level set at 5%. Continuous data
was summarized using descriptive statistics, specifically the
number of observations (N), mean, standard deviation, median,
minimum, and maximum. Categorical data was summarized
using frequency counts and percentages.
Results
Between October 5, 2011 and June 7, 2016, a total of 924
subjects underwent a spinal procedure during which 489 sub-
jects received DuraSeal Exact Spine Sealant (DESS arm) and
435 subjects received other products and/or treatments (control
arm) to close the dura (Figure 1).
Median age of the enrolled subjects was 61 and 501 (54.2%)
were female (Table 1). Of the total, 817 (90.1%) subjects were
white. There was a statistically significant difference in gender
and height between the two treatment arms before controlling
for the propensity score (gender, P < .0001; height, P¼ .0002).
After controlling for the propensity scores, no statistically sig-
nificant difference in any of the subject characteristics was
reported between the treatment arms.
A higher proportion of subjects had involvement of a lumbar
level followed by sacral, thoracic, and cervical levels of the
Kim et al 273
spine. A statistically significant higher proportion of subjects in
the DESS arm underwent a procedure in the lumbar spine
(P ¼ .0230); in contrast, a statistically higher proportion of
subjects in the control arm underwent a procedure in the
cervical spine (P < .0001) compared with other levels (Table 1).
As demonstrated in Table 2, there was no statistically sig-
nificant difference in the duration of the procedures
(P ¼ .0521) or the use of suture/nonsuture repairs
(P ¼ .4481) between the DESS arm and the control arm). The
length of the suture repair was longer for patients in the DESS
arm (P ¼ .0139). There was a statistically higher rate of
incidental dural openings as compared to intentional dural
openings in the control arm (P ¼ .0059). Also, there was a
statistically higher percentage of shunts and drains used in the
control group (P ¼ .0039).
The data set was subdivided into the Per Protocol Analysis
Set (PPAS) and the Safety Analysis Set (SAS) endpoint anal-
ysis. The primary efficacy endpoint was analyzed in both PPAS
and SAS subgroups and the secondary endpoints were analyzed
using only the SAS.
The SAS included all subjects who were enrolled in the
study (N ¼ 924). The PPAS (N ¼ 886) is a subset of the SAS,
which included subjects from the SAS who did not deviate
significantly from the protocol.
Figure 1. Enrollment and study participation schematic.
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Primary Endpoint Results
Ninety-Day Postoperative CSF Leak. For the primary endpoint,
58 (6.6%) subjects (DESS arm, 30 [6.6%]; control arm, 28
[6.5%]) in PPAS experienced a CSF leak within 90 days
after the spine surgical procedure (Table 3). The difference
estimates and 95% CI (%) between treatment arms were
reported as 0.9 (3.7, 2.0) from nonjustified analysis and
as 0.5 (3.4, 2.3) from a propensity score justified anal-
ysis (Table 4). The upper limit of a one-sided 95% CI for
the difference in estimated probability of CSF leak between
the treatment arms 90 days postoperatively (DESS arm 
control arm) was 2.0% from the unstratified analysis and
2.3% from the stratified analysis by propensity score. This
which is far less than the 5% noninferiority margin) and
thus the non-inferiority conclusion was confirmed, as also
noted with SAS group.
Time to First CSF Leak. Time to first CSF leak was defined as the
number of days between the date of surgery and the date of CSF
leak. Per Kaplan-Meier analysis, lack of CSF leak was cen-
sored at the date of last contact for subjects who were lost to
follow up. There was no statistically significant difference in
the time to first CSF leak between the DESS arm and the
control arm (P ¼ .836).
Secondary Endpoint Results
There was no statistically significant difference in the propor-
tion of subjects with DSSIs between DESS and Control arms
(1.6% vs 2.1%; P ¼ .6160) (Table 5). Nor was there any sta-
tistically significant difference in the proportion of subjects
with a neurological SAE between DESS and control arms
(Table 5). Ninety-two subjects experienced at least 1 AE (Dur-
aSeal Exact Spine Sealant arm, 51 [10.4%] subjects; control
Table 2. Surgical Procedure Characteristics (Safety Analysis Set).a
Parameter Spine Sealant Control All P
Duration of procedure (h) 489 432 921 .0521
Mean (SD) 3.6 (2.03) 3.9 (2.16) 3.7 (2.09)
Median 3.2 3.4 3.3
Range (min, max) 1, 13 1, 15 1, 15
Cause of dural opening, n (%) 488 430 918 .0059
Incidental 309 (63.3) 309 (71.9) 618 (67.3)
Intentional 179 (36.7) 121 (28.1) 300 (32.7)
Sutures used for dural opening? n (%) 486 428 914 .4481
Yes 411 (84.6) 354 (82.7) 765 (83.7)
No 75 (15.4) 74 (17.3) 149 (16.3)
Total length of dural incision (cm) 146 52 198 .0139
Mean (SD) 1.5 (1.75) 1.0 (1.22) 1.4 (1.64)
Shunts/drains placed, n (%) 489 435 924 .0039
Yes 221 (45.2) 238 (54.7) 459 (49.7)
No 268 (54.8) 197 (45.3) 465 (50.3)
a Percentages are based on the number of subjects having a non-missing value for the parameter.
Table 1. Baseline Patient Characteristics and Surgical Information (Safety Analysis Set).
Parameter Spine Sealant Control All P
Age (n) 489 435 924 .1983
Mean (SD) (years) 58.8 (15.14) 57.5 (16.32) 58.2 (15.71)
Median (years) 61.0 61.0 61.0
Range (min, max 18, 92 19, 89 18, 92
Sex, n (%) 489 435 924 <.0001
Male 257 (52.6) 166 (38.2) 423 (45.8)
Female 232 (47.4) 269 (61.8) 501 (54.2)
Body mass index (n) 441 360 801 .2797
Mean (SD) (kg/m2) 29.1 (6.36) 29.7 (6.83) 29.4 (6.58)
Median (kg/m2) 28.0 29.0 29.0
Range (min, max) 16, 55 16, 74 16, 74
Spinal levels involved, n (%)
Lumbar 364 (74.4) 295 (67.8) 659 (71.3) .0230
Sacral 138 (28.2) 132 (30.3) 270 (29.2) .4910
Thoracic 115 (23.5) 87 (20.0) 202 (21.9) .1909
Cervical 65 (13.3) 113 (26.0) 178 (19.3) <.0001
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arm, 41 [9.4%] subjects). There was no statistically significant
difference in the proportion of subjects with at least 1 AE
between the DESS arm and control arm (P ¼ .6109).
A total of 75 SAEs were reported during the study, with no
unanticipated adverse device effects (DESS arm, 42 [8.6%]
subjects; control arm, 33 [7.6%] subjects) and no statistically
significant difference in the proportion of subjects with at least
1 SAE between the DESS arm and the control arm (8.6% vs
7.6%; P ¼ .5755).
Finally, there was no statistically significant difference in
the proportion of subjects between the treatment groups in
terms of AE relatedness to the study device (P ¼ .5370) and
AE severity (P ¼ .5979).
Discussion
In many clinical situations, primary dural closure is either not
feasible or inadequate to ensure watertight dural closure. CSF
leakage rate after spinal surgery may vary depending on patient
age, surgical technique, prior spinal operations, and the indi-
cation for surgery.16 The reported CSF leakage rate in inten-
tional durotomies varies from 10% in intradural spinal tumor
resection to even higher rate for surgeries for tethered spinal
cord syndrome or Chiari malformation.17 Retrospective series
in the literature report failure rates between 5% and 10% in
incidental durotomies, requiring reoperations.1,2 Postoperative
CSF leak can first be managed by conservative strategies such
Table 3. Postoperative Cerebrospinal Fluid (CSF) Leak (Per Protocol Analysis Set).a
Spine Sealant, n (%) Control, n (%) All, n (%)
Did subject experience a postoperative CSF leak? 452 434 866
Yes 30 (6.6) 28 (6.5) 58 (6.6)
No 399 (88.3) 382 (88.0) 781 (88.1)
Not noted 0 16 (3.7) 16 (1.8)
Assessment not done 23 (5.1) 8 (1.8) 31 (3.5)
CSF leak was manifested by 30 28 58
Incisional 12 (40.0) 14 (50.0) 26 (44.8)
Neuropathy exam 3 (10.0) 2 (7.1) 5 (8.6)
Imaging study 17 (56.7) 10 (35.7) 27 (46.6)
Other 7 (23.3) 4 (14.3) 11 (19.0)
Was fluid tested for CSF? 30 28 58
Yes 5 (16.7) 2 (7.1) 7 (12.1)
No 25 (83.3) 26 (92.9) 51 (87.9)
Fluid CSF tested result 5 2 7
Positive 5 (100.0) 2 (100.0) 7 (100.0)
Negative 0 0 0
Inconclusive 0 0 0
Imaging study result 17 10 27
Confirmed CSF leak 12 (70.6) 8 (80.0) 20 (74.1)
Not confirmed as a CSF leak 3 (17.6) 2 (20.0) 5 (18.5)
Other 2 (11.8) 0 (0.0) 2 (7.4)
a Percentages are based on the number of subjects having a non-missing value for the parameter.
Table 4. Primary Endpoint: Estimated Probability of Cerebrospinal Fluid (CSF) Leak at 90-Day Postoperative (Per Protocol Analysis Set).
Spine Sealant
Arm (N ¼ 452)
Control
Arm (N ¼ 434)
Difference in Estimated Probability of CSF Leak Between Treatment
Groups at 90 Days Postoperative (DuraSeal  Control) and 95% CI
Unstratified Stratified by Propensity Score Quintile
No. (%) of subjects had CSF leak 30 (6.6) 28 (6.5)
Estimated probability of CSF leak
at 90 days and 95% CI (%)
6.1 (4.2, 8.0) 7.0 (4.9, 9.1) 0.9 (3.7, 2.0) 0.5 (3.4, 2.3)





Subjects with any surgical site
infections, n
463 426 .2295
No 443 (95.7) 414 (97.2)
Yes 20 (4.3) 12 (2.8)
Type of surgical site infections
Deep 7 (1.6) 9 (2.1) .6160
Superficial 13 (2.8) 2 (0.5) .0076
Organ space 0 (0.0) 1 (0.2) .4792
Neurological serious adverse events
Subjects with any neurological
serious adverse event
14 (2.9) 7 (1.6)
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as the use of brace, bedrest, lumbar intrathecal drain, or epi-
dural blood patches.3 Persistent leakage may be addressed by
reoperation, in addition to conservative measures.18
DuraSeal Exact Spine Sealant System (DESS) is the only
FDA-approved secondary agent for dural closure in spine.19 In
addition to its low-swell property, DESS has other key advan-
tages. It remains in situ for about 4 to 8 weeks, much longer
comparedwith other sealants such as a fibrin sealant (5-7 days).20
DESS is entirely synthetic unlike a fibrin product, obviating the
risk of any disease transmission. It is easy to apply and a blue dye
enables easy distinction from blood and CSF.
This postapproval study evaluated DESS in both intentional
and incidental spinal durotomies in comparison to a myriad of
currently used alternatives. Patients of all demographics under-
going spinal operations for variety of indications were included
in this study to reflect a real-world scenario. The sample size
and follow-up were robust to capture potential adverse effects
associated with its use. The primary endpoint was occurrence
of postoperative CSF leaks within 90 days of the operation.
This analysis was restricted to a subgroup of patients who
adhered to the protocol of the study. There was no significant
difference in the postoperative CSF leakage rate between the 2
groups and no significant difference in the time to first leak.
Unlike previous studies that favored a PEG sealant, the
control group had similar CSF leakage rate to the DESS
group.8,15 Previous studies were randomized and limited to
intentional durotomies whereas this study was not randomized
and also included incidental durotomies, which are often more
challenging to address. In addition, for the control group, the
subjects were both prospectively and retrospectively enrolled.
Similar to previous randomized studies, the safety of DESS
was confirmed in this study. No significant difference in deep
surgical site infection rate (1.6% vs 2.1%, P ¼ .61) or neuro-
logical serious adverse events between the 2 groups (P ¼ .53)
were found. There was no statistically significant difference in
the proportion of subjects with at least 1 adverse event between
the 2 groups (10.4% sealant arm vs 9.4% in control, P ¼ .61).
Regardless of the intrinsic differences in the groups such as the
indication for surgery and the type of operation, the rates of
neurological serious adverse events were similar.
This study did find a significantly higher rate of superficial
skin infection with DESS arm (2.8% vs 0.5% in control arm).
Several risk factors are known to be predictive of surgical site
infection such as diabetes, preoperative steroid use, high body
mass index, female sex and inpatient status.21,22 We did not find
any such difference between the 2 groups after adjusting for
propensity scores. Two cases of transcutaneous exudation of
DuraSeal have been reported in the literature but no similar
incidents were noted in this study.23 The most plausible expla-
nation for the difference in superficial skin infection is the fact
that for much of the control group, the data for infection was
recorded retrospectively. Retrospective review of medical
records is not expected to capture all adverse events as would
be the case with the prospective data collection in the DESS arm.
More realistic and consequential concern is the reported
neurological complication from the expansion of the original
formulation of DuraSeal. In a canine model study, the peak
expansion of DuraSeal was noted between 3 and 14 days after
application, and complete resolution was noted at 8 weeks.20
The onset of complication due to expansion in clinical settings
range from few hours to days. In a case of anterior cervical
decompression and fusion, when DuraSeal was used as the only
treatment for incidental durotomy, progressive quadriparesis
developed within 3 hours.24 In a patient who underwent poster-
ior fossa decompression for Chiari malformation, DuraSeal
reportedly led to spinal cord compression with worsening
quadriparesis noted couple of weeks after the surgery.25 In the
lumbar spine, patients who underwent discectomy and inter-
body fusion developed symptomatic thecal sac compression 2
and 9 days after the operations.9,10,14 One patient with cervical
spinal cord compression after anterior cervical discectomy and
instrumented fusion did not undergo revision surgery and had
symptomatic and radiographic resolution at 8 weeks.26 All of
these reported complications resulted from the use of the orig-
inal formulation of DuraSeal known to swell 38% more than
the low swell formulation.
Duraseal Exact Spine Sealant has a very low expansion rate
of 19%, substantially reducing the risk of neural compression.
To date, no clinical case of neurologic complication due to
expansion of DESS has been reported in the literature. As a
general rule, DESS should not be used in very confined space
such as in anterior cervical discectomy, and only a thin layer
should be applied when used elsewhere. Adequate hemostasis
should be achieved before closure to prevent additional mass
effect from hematoma.12
The nonrandomized, multicenter design of the present study
is associated with several confounding variables. Although a
direct comparison of the efficacy of DESS is difficult, this
study confirmed its safety. Neither were cases of swelling
reported nor were any subsequent complications from swelling
noted in the prospectively enrolled DESS arm. Large sample
size across multiple surgical indications and demographics
reflecting a real-world clinical practice led to our conclusion
of its safety. It is the only FDA-approved adjunct to closure of
dura mater in the spine. Duraseal Exact Spinal Sealant System
(PEG spinal sealant) should be used instead of the conventional
PEG sealant (DuraSeal) in the spine.
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